Aimmune Therapeutics Inc. (AIMT) Stock Price Up 3.8%
Shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) rose 3.8% on Wednesday . The stock traded as high as $10.99 and last traded at $10.87, with a volume of 88,983 shares changing hands. The stock had previously closed at $10.47.
AIMT has been the subject of several research reports. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a report on Wednesday, June 29th. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a research report on Monday, May 16th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, May 20th. Five investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $33.40.
The firm’s market capitalization is $449.51 million. The company’s 50-day moving average is $13.38 and its 200 day moving average is $14.78.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.03. Equities analysts forecast that Aimmune Therapeutics Inc. will post ($1.70) earnings per share for the current fiscal year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
A number of institutional investors recently modified their holdings of the company. Aisling Capital LLC raised its position in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares during the period. TLP Group LLC bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000. Alps Advisors Inc. bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $1,027,000. Finally, Eagle Asset Management Inc. bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $15,794,000.
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.